The Priority Review

The stream · Daily digest

The stream: Monday, November 9, 2026

7 briefs from ClinicalTrials.gov and FDA, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 4

  1. Anaheim Bio lève 40 millions d'euros en série A

    Anaheim Bio a annoncé un financement de série A sursouscrit de 40 millions d'euros, assuré par Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest et Thuja Capital. Le capital permettra de franchir les études préparatoires à l'IND et d'entrer en phase 1 pour l'ANA-1, un candidat thérapeutique contre la maladie de dépôt de pyrophosphate de calcium.

    Source: Company press release (PR Newswire), November 9, 2026

  2. CSPC Megalith Biopharmaceutical registers Phase III trial of enlonstobart with SYS6010

    The trial plans to enroll 585 participants, beginning on December 30, 2026, with a primary completion date of December 30, 2029. It is a randomized, controlled, double-blind, multicenter Phase III study evaluating the efficacy and safety of enlonstobart with or without SYS6010 in participants with pathologically residual esophageal squamous cell carcinoma after complete surgical resection.

    Source: ClinicalTrials.gov registry record, November 9, 2026

  3. Ascendis Pharma registers Phase 3 trial of navepegritide and lonapegsomatropin in achondroplasia

    The study, led by Ascendis Pharma A/S, plans to enroll 144 participants and start in November 2026. It compares dual therapy with navepegritide and lonapegsomatropin to navepegritide monotherapy and lonapegsomatropin monotherapy in children and adolescents with achondroplasia.

    Source: ClinicalTrials.gov registry record, November 9, 2026

  4. Hoffmann-La Roche posts results of Phase III tiragolumab trial in NSCLC

    The study, completed with 620 participants, compared tiragolumab plus atezolizumab to placebo plus atezolizumab in patients with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer. Primary completion occurred on December 30, 2025, and the trial was registered as NCT04294810.

    Source: ClinicalTrials.gov results record, November 9, 2026

Approvals · 2

  1. FDA approves Sunharbo for secondary stroke prevention

    The FDA approved Sunharbo (asundexian) 50 mg tablets on November 09, 2026 for adults at high risk of stroke after a mild-to-moderate non-cardioembolic ischemic stroke or high-risk TIA. The OCEANIC-STROKE phase 3 study enrolled 12,327 participants and found Sunharbo 50 mg once daily significantly reduced the risk of ischemic stroke by 26 % compared to placebo over a median treatment of 14.2 months.

    Source: FDA approval notification, November 9, 2026

  2. Johnson & Johnson FDA grants accelerated approval for RYBREVANT FASPRO in head and neck cancer

    The FDA granted accelerated approval for RYBREVANT FASPRO as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval was based on the Phase 1b/2 OrigAMI-4 trial, in which the confirmed overall response rate was 42 percent per blinded independent central review.

    Source: Company press release (PR Newswire), November 9, 2026

Policy · 1

  1. PharmaLogic to acquire Lantheus CDMO business and Springfield facility

    PharmaLogic announced a definitive agreement to acquire Lantheus' CDMO business and the Springfield, New Jersey manufacturing facility, expanding its U.S. radiopharmaceutical manufacturing capacity. The transaction includes a long-term supply agreement under which Agilera will manufacture lutetium Lu-177 dotatate for Lantheus.

    Source: Company press release (PR Newswire), November 9, 2026